Essays on diagnostics sovereignty: how Gulf and European health systems secure reagents, instruments, and manufacturing so they are not hostage to fragile global supply chains
A Blackout, Toilet Paper, and GCC Diagnostics How the Gulf exports the raw material for molecular medicine, and imports every finished piece of it The Gulf Cooperation Council (GCC) has invested heavily in genomics, cancer care, and national screening programmes, but the region’s diagnostics manufacturing base remains thin. This essay argues that single-use laboratory plasticware…
As the Strait of Hormuz crisis intensifies and persists, major container lines have suspended or rerouted Gulf calls around the Cape of Good Hope, adding ten to fourteen days to deliveries of medical devices, consumables, and diagnostic inputs. Freight and insurance costs spiked. Airspace restrictions compounded the disruption: medical and humanitarian supplies including IV fluids,…
Over the past several weeks I have been reading the many analyses coming out of Gulf policy circles. Carnegie’s three scenarios for GCC states after the Iran war. The Al Jazeera opinions arguing that joint defence and integrated development are now the only credible regional agenda. The Middle East Council’s assessment of Qatar’s strategic position…
The MDS-G022 lays the foundation for a GCC-wide in-house IVD framework. This matters for diagnostics sovereignty and early commercial development in the Gulf In May 2025, the Saudi Food and Drug Authority published Version 2.0 of MDS-G022, its guidance on in-house IVDs. Most commentary has treated it as a compliance update for lab managers. I want…
A note from work in progress: The Import Condition: Diagnostics, Sovereignty, and the Gulf’s Industrial Moment There is a dependency in Gulf healthcare that does not appear on any customs manifest and generates no import tariff. It does not show up in the trade statistics for diagnostic reagents. It cannot be measured in tonnes at…
Published on Linkedin on April 5, 2026 A simple blood count is not a glamorous, high-tech, innovation-driven precision medicine, AI-powered solution. It is not the next shiny thing that makes investors and bureaucrats alike very excited. Yet every hospital in the Gulf runs hundreds, maybe thousands of them every day. Haematology panels, biochemistry screens, urine…
Published on LinkedIn on Dec 1st, 2025 In the global race for medical innovation, market size matters, but market access matters more. Today, a medical device manufacturer targeting the Gulf Cooperation Council (GCC) faces a paradoxical reality. They (we!) see a wealthy, integrated economic bloc of 60+ million people with world-class healthcare infrastructure. Yet, when…
Published on Linkedin on Nov 23rd I visited Wuhan once, in 2004, teaching for a couple of weeks as part of EMBO’s World Program. I can’t claim the trip left me with profound insights about China – the city was unremarkable if enormous, nothing that prepared me for what it would become or mean to…
Published on LinkedIn on Nov 20th In Part 1/2 (https://www.linkedin.com/pulse/rebuilding-case-diagnostics-investment-12-reflections-pereira-leal-swvbf), I discussed why diagnostics face a systematic funding gap despite being essential infrastructure for precision medicine, and outlined five strategic directions for entrepreneurs building diagnostic companies. Those reflections emerged from building Ophiomics and follow from the reflection I’ve been making for my book, Precision Diagnostics:…
Published on LinkedIn on Nov 17th The diagnostics sector faces a paradox: we’re living through a precision medicine revolution, yet the tools that make precision medicine possible remain chronically underfunded. In 2023-2024, diagnostics captured just $2.2 billion in global venture funding, while AI companies raised over $100 billion globally in 2024. Even within healthcare, nearly…